title: Percutaneous, oral, or intravesical BCG administration: what is the optimal route?
authors.affiliation: Department of Urology, West Virginia University, Morgantown.
authors.forename: D L
authors.initials: DL
authors.lastname: Lamm
authors.forename: M S
authors.initials: MS
authors.lastname: Sarodosy
authors.forename: J I
authors.initials: JI
authors.lastname: DeHaven
mesh_terms: D000279:Administration, Cutaneous; D000283:Administration, Intravesical; D000284:Administration, Oral; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D001500:BCG Vaccine